Impact of KRAS mutation on response and outcome of patients with stage III non‐squamous non‐small cell lung cancer

Cancer Science

Shigehiro Yagishita¹  Hidehito Horinouchi¹  Kuniko S. Sunami¹  Shintaro Kanda¹  Yutaka Fujiwara¹  Hiroshi Nokihara¹  Noboru Yamamoto¹  Minako Sumi²  Kouya Shiraishi³  Takashi Kohno³  Koh Furuta⁵  Koji Tsuta⁴  Tomohide Tamura¹ 

[1]Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan

[2]Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan

[3]Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan

[4]Department of Pathology, National Cancer Center Hospital, Tokyo, Japan

[5]Department of Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan

关键词: Biomarkers;    chemoradiotherapy;    KRAS;    non‐small cell lung cancer;    relapse;   

DOI  :  10.1111/cas.12740

来源: Wiley

【 摘 要 】

Abstract

The frequency and clinical profile of patients with stage III non-small cell lung cancer harboring KRAS mutations have not yet been well documented. Here, we analyzed hotspot KRAS mutations using high-resolution melting analyses in tumor specimens from patients who received chemoradiotherapy between January 2001 and December 2010 at the National Cancer Center Hospital. The associations between the presence of KRAS mutations and the response rate, relapse-free survival, first relapse sites, survival post-progression and overall survival were investigated. A total of 274 non-squamous non-small cell lung cancer patients received chemoradiotherapy at our hospital. After excluding 121 patients for whom tumor specimens were not available and 34 patients with EGFR mutations, the remaining 119 patients were included in the analysis. KRAS mutations were found at a frequency of 13%. Patients with KRAS mutations had a shorter median relapse-free survival (6.1 vs 10.9 months) and a lower response rate (63% vs 81%). As for the first relapse site, patients with KRAS mutations had fewer local relapses (8% vs 23%) and more brain metastases (46% vs 12%). After disease progression, patients with KRAS mutations had a significantly shorter median survival post-progression (2.5 vs 7.3 months, P = 0.028) and median overall survival (15.1 vs 29.1 months, P = 0.022). Our results suggested that KRAS mutation could be associated with a reduced efficacy of chemoradiotherapy and a shortened survival time.

【 授权许可】

CC BY-NC   
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.